Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
Targets |
ROR-γ 63.8 nM (IC50)
|
---|---|
ln Vitro |
In the Th17 cell differentiation experiment, RORγt inverse agonist 13 (Compound 3i) shows action with an inhibition of 76% at 0.3 µM[1].
|
ln Vivo |
In an IMQ-induced psoriasis mouse model, RORγt inverse agonist 13 (Compound 3i, 25 mg/kg, Orally, twice daily) has good in vivo effectiveness and an outstanding in vivo PK profile[1].
|
Animal Protocol |
Animal/Disease Models: Imiquimod (IMQ) -induced psoriasis mice model[1].
Doses: 25 mg/kg. Route of Administration: Orally, twice (two times) daily. Experimental Results: Brought in a significant reduction in clinical severity of psoriasis as measured through the ear erythema, back skin erythema and scaliness scales. Animal/Disease Models: Male CD-1 Mice[1]. Doses: 1 mg/kg (iv) and 5 mg/kg (po)(pharmacokinetic/PK Analysis). Route of Administration: IV or PO, single dose. Experimental Results: Cmax: 609.67 ng/mL (PO), 1550 ng/mL (IV). T1/2: 3.63 h (PO), 3.04 h (IV). |
References |
[1]. Nannan Sun, et al. Discovery of carboxyl-containing biaryl ureas as potent RORγt inverse agonists. Eur J Med Chem. 2020 Jul 5;202:112536.
|
Molecular Formula |
C23H17CL2F3N2O4
|
---|---|
Molecular Weight |
513.29
|
CAS # |
2170477-75-3
|
SMILES |
ClC1C([H])=C(C([H])=C(C=1C1=C([H])C([H])=C([H])C([H])=C1OC(F)(F)F)Cl)N([H])C(N([H])C([H])([H])C1C([H])=C([H])C(C([H])([H])C(=O)O[H])=C([H])C=1[H])=O
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 100 mg/mL (194.82 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.87 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9482 mL | 9.7411 mL | 19.4822 mL | |
5 mM | 0.3896 mL | 1.9482 mL | 3.8964 mL | |
10 mM | 0.1948 mL | 0.9741 mL | 1.9482 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.